HopeStage
Back to overview

Schizophrenia studies

Topics
More filters

Schizophrenia

Schizophrenia can affect how a person perceives reality, thinks and feels, sometimes involving hearing voices or holding unusual beliefs.

4505studies shown
Showing 3,013-3,024 of 4,505
Drug study icon
CompletedNCT01362439

Switching From Oral Antipsychotics to Extended-Release Paliperidone

About this title

Paliperidone Extended Release in Schizophrenia Participants With Duration of Illness Less Than 10 Years

Read the official source — NCT01362439
What is this study about?

Researchers studied Paliperidone ER to find out how it affected psychotic symptoms in people with schizophrenia.

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–45
Countries
Sponsor
Janssen-Cilag S.p.A.
Drug study icon
CompletedNCT01154829

Brain and Thinking Measures After Antipsychotic Treatment Begins

About this title

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS)

Read the official source — NCT01154829
Official study title

Pan European Collaboration on Antipsychotic Naive Schizophrenia (PECANS): the Effects of D2 Antagonism on Candidate Endophenotypes

This study has finished and is no longer accepting participants.

In Glostrup Municipality
SchizophreniaMedication studyAges 18–45
Countries
Denmark
Sponsor
University of Copenhagen
Other study type icon
CompletedNCT02634671

Perception of Facial Emotions in Schizophrenia and 22q11 Deletion Syndrome

Official study title

Facial Expression Perception by Intensity in Schizophrenia and 22q11.2 Deletion Syndrome: Neural Electrophysiological Evidence by Means of Fast Periodic Visual Stimulation

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaInterventional studyAges 15–50
Countries
Sponsor
Hôpital le Vinatier
Drug study icon
CompletedNCT04787302

PET study to Evaluate Target Occupancy of CVL-231 on Brain Receptors Following Oral Dosing

Official study title

A Phase 1, Open-label Trial to Evaluate Target Occupancy of CVL-231 at Muscarinic Receptors Type 4 in Brain Following Single Oral Doses Using Positron Emission Tomography in Healthy Adult Subjects

This study has finished and is no longer accepting participants.

Multiple locations, including Boston
SchizophreniaMedication studyAges 18–55
Countries
United States, Belgium
Sponsor
Cerevel Therapeutics, LLC
Drug study icon
CompletedNCT05106309

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

Official study title

A Phase 1, Open-label Trial to Evaluate the Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations Under Fasted and Fed Conditions in Healthy Participants

This study has finished and is no longer accepting participants.

In Tempe
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
Cerevel Therapeutics, LLC
Drug study icon
CompletedNCT02748694

Phase 1 TAK-041 First-in-Human Safety, Tolerability, and Pharmacokinetics Study

Official study title

A Randomized, Double -Blind, Placebo-Controlled, Phase 1, Ascending Oral Single and Multiple Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAK-041 in Healthy Subjects and Subjects With Stable Schizophrenia and a Randomized Open-Label, Single Dose, Parallel Design to Evaluate the Relative Bioavailability and Effect of Food on the Pharmacokinetics of TAK-041 Tablet Formulation in Healthy Subjects

This study has finished and is no longer accepting participants.

In Glendale
SchizophreniaMedication studyAges 18–55
Countries
United States
Sponsor
Neurocrine Biosciences (Biotech company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.